Androgen receptor regulates CD168 expression and signaling in prostate cancer

Carcinogenesis

Volumn 29, Issue 2, 2008, Pages 282-290

  Lin, Shi Lung ^a   Chang, Donald ^a   Chiang, Angela ^a   Ying, Shao Yao ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; CARBOHYDRATE BINDING PROTEIN; CD168 ANTIGEN; HYALURONIC ACID; RHO KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; ENDOTHELIUM CELL; ENZYME INHIBITION; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD44; BONE MARROW CELLS; CELL LINE, TUMOR; DIHYDROTESTOSTERONE; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 40549131045     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm259     Document Type: Article

References (30)

1. Zhou,J. et al. (2001) Signal transduction targets in androgen-independent prostate cancer. Cancer Metastasis Rev., 20, 351-362.
2. Paszek,M.J. et al. (2005) Tensional homeostasis and the malignant phenotype. Cancer Cell, 8, 241-254.
3. Lin,S.L. et al. (2007) Hyaluronan stimulates transformation of androgenindependent prostate cancer. Carcinogenesis, 28, 310-320.
4. Shah,R.B. et al. (2004) Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res., 64, 9209-9216.
5. Cheng,Y.G. et al. (2002) Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp. Biol. Med., 227, 75-87.
6. Ying,S.Y. et al. (2004) Gene expression in precursor cells of prostate cancer associated with activin by combination of subtractive hybridization and microarray technologies. Biochem. Biophys. Res. Commun., 313, 104-109.
7. Laurent,T.C. et al. (1992) Hyaluronan. FASEB J., 6, 2397-2404.
8. Turley,E.A. (1992) Hyaluronan and cell locomotion. Cancer Metastasis Rev., 11, 21-30.
9. Toole,B.P. et al. (2005) Hyaluronan: a critical component of epithelialmesenchymal and epithelial-carcinoma transitions. Cells Tissues Organs, 179, 66-72.
10. Csoka,T.B. et al. (1997) Hyaluronidases in tissue invasion. Invasion Metastasis, 17, 297-311.
11. Delpech,B. et al. (1997) The origin of hyaluronectin in human tumors. Int. J. Cancer, 72, 942-948.
12. Itoh,K. et al. (1999) An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat. Med., 5, 221-225.
13. Somlyo,A.V. et al. (2003) Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants. FASEB J., 17, 223-234.
14. Bourguignon,L.Y.W. et al. (2003) Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J. Biol. Chem., 278, 29420-29434.
15. Rodriguez-Viciana,P. et al. (1996) Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J., 15, 2442-2451.
16. De Benedetti,A. et al. (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene, 23, 3189-3199.
17. Aaltomaa,S. et al. (2002) Strong stromal hyaluronan expression is associated with PSA recurrence in local prostate cancer. Urol. Int., 69, 266-272.
18. Liu,A.Y. et al. (2004) Heterogeneity in primary and metastatic prostate cancer as defined by cell surfaceCDprofile. Am. J. Pathol., 165, 1543-1556.
19. Dhir,R. et al. (1997) CD44 expression in benign and neoplastic human prostates. Mol. Diagn., 2, 197-204.
20. Pilarski,L.M. et al. (1994) RHAMM, a receptor for hyaluronan-mediated motility, on normal human lymphocytes, thymocytes and malignant B cells: a mediator in B cell malignancy? Leuk. Lymphoma, 14, 363-374.
21. Nedvetzki,S. et al. (2004) RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Proc. Natl Acad. Sci. USA, 101, 18081- 18086.
22. Hofmann,M. et al. (1998) Problems with RHAMM: a new link between surface adhesion and oncogenesis? Cell, 95, 591-593.
23. Bjornsti,M.A. et al. (2004) Lost in translation: dysregulation of capdependent translation and cancer. Cancer Cell, 5, 519-523.
24. Miyamoto,H. et al. (2005) Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Mol. Carcinog., 44, 1-10.
25. Grossmann,M.E. et al. (2001) Androgen receptor signaling in androgenrefractory prostate cancer. J. Natl Cancer Inst., 93, 1687-1697.
26. Litvinov,I.V. et al. (2006) PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate, 66, 1329-1338.
27. Lin,S.L. et al. (2005) Gene silencing in vitro and in vivo using intronic microRNAs. In Ying,S.-Y. (ed.) MicroRNA Protocols. Humana press, Totowa, NJ, pp. 295-312.
28. Rockwell,S.C. et al. (1972) Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J. Natl Cancer Inst., 49, 735-749.
29. Blok,L.J. et al. (1992) Transcriptional regulation of androgen receptor gene expression in Sertoli cells and other cell types. Mol. Cell. Endocrinol., 88, 153-164.
30. Chang,C.S. et al. (1998) Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc. Natl Acad. Sci. USA, 85, 7211-7215.